You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.
Samples collected over time from more than 300 SARS-CoV-2-infected young adults pointed to prolonged viral shedding in symptom-free individuals.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
PharmaCyte licensed the RT-PCR and enhanced fluorescence RT-PCR tests from Hong Kong-based Hai Kang Life.
The firm saw revenues grow 10 percent in Q2, in part driven by PCR-based COVID-19 testing, as it increased production capacity to 10 million tests per week.
About $1.3 billion of revenues, or 19 percent, were related to COVID-19 products and services, and life sciences solutions revenues jumped 52 percent.
Users will be able to sequence over 20,000 samples simultaneously with the updated panel, which the firm expects to offer sometime in the third quarter for research use only.
Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.
The firm said that its RAQ SARS-CoV-2 PCR Kit allows the replacement of full nucleic acid extraction with a simple heat treatment, decreasing sample processing time.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.